We are proud to announce that Eagle IP has been ranked once more in Tier 1 (the highest tier) for Patent Prosecution in the IP Stars 2026 Patent Firms Ranking by Managing IP. The rankings cover over 70 jurisdictions worldwide and recognize the top recommended firms for patent filing, prosecution, and disputes work. This Tier 1 placement is a testament to the positive feedback our clients have provided to Managing IP during their annual reviews.

It is with great pride that we have been included in this highest category among just a select few top firms in Hong Kong. We are deeply grateful to Managing IP for this recognition of our work. At Eagle IP, we are dedicated to providing exceptional service to our clients by drawing upon our hands-on knowledge of US and Chinese patent law, our proven ability to craft sophisticated and creative patent strategies, and our strong technical expertise. We will continue to build upon these strengths to deliver the highest level of service and support to the innovators who entrust us with protecting their groundbreaking ideas.

As always, a huge THANK YOU to all our clients, mentors, and colleagues who have supported us through the years.

我們過去活動

Eagle IP Achieves Top Ranking in 2026 IAM Patent 1000

2026年6月2日

Eagle IP to Participate in AIPLA 2026 Spring Meeting in San Francisco

2026年5月8日

Eagle IP has been named as the Winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026

2026年5月8日

Eagle IP to Attend INTA 2026 Annual Meeting in London

2026年5月2日

Eagle IP’s Jennifer Che to Attend LSPN North America Spring 2026 in Boston

2026年4月29日

Pauli Wong to Share IP Strategy Insights at HKLSS Entrepreneurship Series 2026

2026年4月25日

Recommended Insights

Everything you need to know about Patent Term Adjustment (PTA) in China

2024年5月7日
We previously discussed patent term compensation for patent office delay (‘Patent Term Adjustment’ or ‘PTA’) when such new system was introduced in the Fourth Amendment of the Chinese Patent Law (2020), as well as in the different versions of the Draft Examination Guidelines released in 2021 and 2022. In this article, we consolidate everything you need to […]
閱讀更多 >

CHINA DIVISIONAL PATENT STRATEGY: Recent Judgment Narrows What Constitutes “Different Inventions” for Divisionals

2021年12月6日
In China, patents applicants take advantage of a commonly-used divisional filing strategy to achieve a fine-tuned balance between protection scope and protection period (if used properly). Patent applicants (especially foreign applicants) widely welcome this well-established strategy, and up until now, have used it with much success. In fact, we recommend this strategy and have even […]
閱讀更多 >

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

2023年12月12日
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]
閱讀更多 >

China Releases Draft Implementation Guidelines for the Drug Administration Law

2022年6月2日
The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]
閱讀更多 >
Top crossarrow-right